Nitrated-fatty acids modulation of type II diabetes

Patent metadata

Field	Value
Publication number	US-10258589-B2
Application number	US-201715629277-A
Country	US
Kind code	B2
Filing date	Jun 21, 2017
Priority date	Aug 1, 2007
Publication date	Apr 16, 2019
Grant date	Apr 16, 2019

Abstract

Nitro oleic acid and related metabolites are agonists of PPAR-γ. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-γ, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-γ.

First claim

What is claimed is:

1. An oral unit dosage form comprising a pharmaceutical composition, the pharmaceutical composition comprising (A) an active agent selected from nitro oleic acid and a metabolite of nitro oleic acid, or a pharmaceutically acceptable salt or prodrug of said active agent, and (B) a pharmaceutically acceptable carrier.

2. The oral unit dosage form of claim 1 , wherein the active agent is nitro oleic acid.

Assignees

• Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education

Inventors

• Freeman Bruce A
• Schopfer Francisco J

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/20

  having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids · CPC title

• A61K31/201 Primary

  having one or two double bonds, e.g. oleic, linoleic acids · CPC title